Targeting Non-cocing RNA Senslizes Cancer Cells to Drugs

摘要

Recently, Costales and colleagues (J. Am. Chem. Soc. 2019141:2960-2974) reported a bivalent small molecule inhibitor of primary miRNA (pri-miR)-515. Perturbation of pri-nniR-515 results in the upregulation of HER2 protein levels, rendering HER2 breast cancer cells more sensitive to Herceptin treatment. This strategy represents a novel pha acological approach to selectively modulating disease-relevant proteins in tumor cells.